Clinical findings from #SABCS21 GS3 in 2 minutes or less. #CleClinicCancer ⁦Cleveland Clinic MD⁩

Past midnight on this side of the Atlantic, but looking forward to this poster discussion! #SABCS21 #BreastCancer #TNBC #Immunotherapy 😴😴

Come & see our Poster “Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, HR+, HER2- mBC” now at #SABCS21
‼️mPFS: 31,7 vs 22,8 months
⚠️HER2low marker of endocrine resistance?
✅PAM50 non-luminal subtypes more prevalent in HER2low

#SABCS21 : #clinicaltrial data of our PR antagonist ONA-XR in early #breastcancer presented by SOLTI #cancerresearch showed decreased proliferation in high PR+ tumors, implying an increased chance of tumor response to anti-estrogen therapy when combined w/ONA-XR. $CNTX ir.contexttherapeutics.com/news-releases/…

⁦Lauryn Werner, PhD⁩ rocking her poster session. Hope I can squeeze through the crowd and embarrass her :) ⁦SABCS⁩ #sabcs21 ⁦KU Cancer Center⁩

Congratulations ⁦Diana Basali⁩ for your #SABCS21 presentation and your ongoing work to better understand disparities in breast cancer outcomes! #CleClinicCancer ⁦Cleveland Clinic MD⁩ ⁦Cleveland Clinic IM⁩

Proud for this to be my inaugural tweet - Anton and Antonio take on San Antonio! Antonio Marra #SABCS21

Delighted to be presenting my research at #SABCS21 . Here are two of the four posters from our Acorn group projects @nicb_dcu Dublin City University Dublin City University_Cancer Dublin City UniversityFSH

Breast cancer-associated germline PV carriers in Mexico
✅61% underwent ≥1 risk-reducing (RR) surgery
✅35% and 34% underwent ≥1 or all, respectively, of the recommended RR surveillance studies
⚠️81% reported ≥1 challenge that hindered the uptake of RR measures
#SABCS21 #BCSM

BioItaLEE supports the role of #ctDNA for early response monitoring in luminal-like #MBC . Decreased mutant allele frequency after 15 days is associated with prognosis in patients treated with first line #EndocrineTherapy + CDK4/6 inhibitors #SABCS21 #bcsm

Alamo Breast Caner Foundation Hot Topics. Always the best session at #SABCS21

A question was asked yesterday during the presentation of SAFIR02 trial during #SABCS21 about efficacy in ESCAT 1 versus 2. Below the detailed data.

Fantastic and highly educational talk by Jennifer Guerriero, PhD at #SABCS21 . Macrophages are a major cellular component in #breastcancer , including BRCA1-associated TNBC - and influenced by microbiome.

If axillary surgery does not contribute to survival and is not necessary for local control, can it be eliminated in more patients and/or do we need to increase its use to more precisely tailor therapy?

Dr. Monica Morrow @sloan_kettering
#SABCS21 #bcsm

gBRCA2m associated inferior outcomes with cdk 4/6i; Rb1 monoallelic loss associated with less benefit to cdk 4/6i

OncoAlert #bcsm #SABCS21

Guess who is on #Twitter Matthew Ellis, MB, BChir, PhD, FRCP BCMHouston #SABCS21

Thanks SABCS for having our poster presentation about #financialtoxicity in #BRCA carriers - the first study of its kind! #SABCS21 #BCSM #previvors #qualityoflife

Live debate #SABCS21 One week of whole breast radiation is the new standard of care? Great debaters, not to be missed #radonc #OncoAlert OncoAlert

#SABCS21 moving forward in TNBC by ⁦Lisa Carey, MD, ScM, FASCO⁩

Fantastic education presentation by Heather McArthur, MD, MPH UTSW Simmons Cancer Center on Immune Therapy in (Neo)adjuvant Setting! #SABCS21